Hundreds of protests at Tesla showrooms have also weighed on the company. Under the banner of a “Tesla Takedown,” opponents ...

Frontotemporal disorders (FTD) encompass a group of neurodegenerative conditions affecting the frontal and temporal lobes of the brain, leading to progressive cognitive and behavioral decline. As ...

GSK's Blenrep (belantamab mafodotin) has officially been approved by the UK's Medicines and Healthcare products Regulatory ...

According to DelveInsight's analysis, the market for GIST is anticipated to increase during the forecast period (2025–2034), owing to the launch of e ...

Growth Drivers include demand for protein-based drugs, rise in chronic disease prevalence, precision medicine expansion, biotech advancements, and AI-driven design tools.Dublin, April 14, 2025 (GLOBE ...

GSK plc (LSE/NYSE: GSK) today announced the recipients of its COiMMUNITY Initiative grant program, awarding nearly $2 million to 15 regional, state and national non-profits and community-based groups ...

The year marked the third-largest contraction of the global art market in the past 15 years, the report found, eclipsed only by the years of the 2009 recession (-36%), and the 2020 Covid-19 ...

Amid the current market turmoil, it is worth remembering that the pharmaceutical industry must continue its normal business of ensuring that it has products to sell in 10 years, with GSK (GSK) signing ...

Octavio Dotel, a major league pitcher for 15 seasons, was reportedly among those trapped in the rubble of a nightclub in the Dominican Republic whose roof collapsed early Tuesday morning. At least ...

NEW YORK, NY / ACCESS Newswire / April 7, 2025 / If you suffered a loss on your GSK plc (NYSE:GSK) investment and want to learn about a potential ...

The IQVIA Institute for Human Data Science has released, Global Trends in R&D 2025 report, Progress in Recapturing Momentum in Biopharma Innovation, which assesses the trends in R&D funding, clinical ...

GSK has continued to flesh out its neuroscience strategy with a 2 billion pound sterling ($2.5 billion) deal to use a South Korean company’s tech to bypass the blood-brain barrier. ABL Bio has ...